. . . . . . . . . "Lintitript is a new, highly specific and potent CCK-A receptor antagonist."@en . . . . "For the treatment of pancreatic cancer and appetite disorders."@en . . . . . . . "Humans and other mammals"@en . . "investigational"@en . . . . . "136381-85-6"@en . . . . . . . "# Kreiss C, Schwizer W, Borovicka J, Jansen JB, Bouloux C, Pignol R, Bischof Delaloye A, Fried M: Effect of lintitript, a new CCK-A receptor antagonist, on gastric emptying of a solid-liquid meal in humans. Regul Pept. 1998 Jun 30;74(2-3):143-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9712175"@en . "Cholecystokinin (CCK) modulates feeding and dopamine-induced behavior in the central and peripheral nervous system. Lintitript antagonizes the effect of cholecystokinin by binding to the cholecystokinin type A (CCK-A) receptor. This action presumably alters feeding habits, however the exact mechanism of action is not known."@en . " "@en . "Lintitript"@en . . . .